Anika Therapeutics Inc. (ANIK) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Anika Therapeutics Inc. (ANIK) advanced +1.11% to $21.79, trading at 92% of its 52-week range ($9.01 – $22.88). Stretched risk/reward at current multiples (-10% return on capital) under elevated 10-year interest-rate pressure.
BEDFORD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2026
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -5.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ANIK today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ANIK. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Anika Therapeutics Inc. (ANIK) ranks #281 by composite RQD confidence (55/100, grade D+) and #522 by equity capitalization ($291.6M). Within this direct 5-issuer industry benchmark cohort, INFU leads on earnings valuation at 43.4x trailing P/E, while INFU leads on capital efficiency and profitability with 12.8% ROIC and 56.0% gross margin. INFU currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with ANIK at 55/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ANIK
ACTIVE
Anika Therapeutics Inc. | D+ | 55/100 | — | 56.6% | -10.2% | +1.11% | $291.6M | Benchmark Subject |
| INFU InfuSystems Holdings Inc. | B+ | 76/100 | 43.4x | 56.0% | 12.8% | +0.91% | $287.8M | /infu-vs-anik → |
| OSUR OraSure Technologies Inc. | E | 32/100 | — | 41.9% | -35.0% | -0.49% | $281.4M | /osur-vs-anik → |
| TMCI Treace Medical Concepts Inc. | D- | 41/100 | — | 79.8% | -32.4% | +4.76% | $329.1M | /tmci-vs-anik → |
| CLPT ClearPoint Neuro Inc. | E | 34/100 | — | 61.4% | -35.0% | +1.23% | $342.7M | /clpt-vs-anik → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Anika Therapeutics Inc. (ANIK) reported GAAP revenue of $112.8M (-5.9% vs. FY2024 revenue of $119.9M , and -6.6% cumulative change since FY2023) , GAAP net income of -$11.0M, operating cash flow of $11.2M, and free cash flow of $4.4M (+287.1% YoY). On the balance sheet, ANIK closed FY2025 with $190.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $112.8M | -$11.0M | $11.2M | $4.4M | $190.3M | — |
| FY2024 (FY) | 2024-12-31 | $119.9M | -$56.0M | $5.4M | -$2.3M | $202.7M | — |
| FY2023 (FY) | 2023-12-31 | $120.8M | -$83.0M | -$1.8M | -$1.8M | — | — |
As of 2026-11-01, Anika Therapeutics Inc. (NASDAQ: ANIK) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $21.79 (+1.11% 1D, market cap $291.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ANIK ranks #281 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), ANIK carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -10.2%. By comparison, INFU (InfuSystems Holdings Inc.) holds a B+ grade (76/100 RQD, P/E 43.4x, ROIC 12.8%, cap $287.8M) and OSUR (OraSure Technologies Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $281.4M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while INFU leads on capital efficiency (12.8% ROIC).
Per ANIK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000898437), Anika Therapeutics Inc. generated $112.8M in revenue (-5.9% YoY), -$11.0M in net income, and $4.4M in free cash flow against $190.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ANIK last traded at $21.79 (+1.11% on volume of 121,771 shares), positioning the stock +5.47% above its 50-day simple moving average ($20.66) and +35.59% above its 200-day simple moving average ($16.07). Across its 52-week range of $9.01 to $22.88, ANIK sits at the 92.1% percentile with a 14-day RSI of 53.1 (NEUTRAL RANGE) and an implied next-earnings move of ±8.2% ($20.00 to $23.58).
Why ANIK Stock advanced +1.11% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-10% return on capital) under elevated 10-year interest-rate pressure.